List of contraindications when using Capmatinib (Touradida) in combination with other drugs

Capmatinib (Capmatinib) is a MET receptor tyrosine kinase inhibitor, mainly used to treat METexon 14 skipping mutation-positive non-small cell lung cancer (NSCLC). In clinical practice, patients may be given combinations with other medications to enhance efficacy or manage concomitant diseases. However, since the metabolism of capmatinib mainly relies on the CYP3A4 enzyme, some drugs may cause abnormal blood concentrations or enhance toxicity, so there are certain contraindications for combined use.

First of all, the combined use of potent CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin) with capmatinib may significantly increase the plasma concentration, thereby exacerbating the risk of side effects, such as abnormal liver function, gastrointestinal discomfort, and prolongation of the QT interval. Therefore, the simultaneous use of such drugs should be avoided. If necessary, the dose of capmatinib should be adjusted or alternative drugs should be selected under the guidance of a doctor.

Secondly, strong CYP3A4 inducers (such as rifampicin, carbamazepine, St. John's wort) may reduce the plasma concentration of capmatinib and reduce its efficacy. Concomitant use may result in treatment failure or disease progression, so patients should avoid these drugs and, if necessary, adjust their regimen or choose an alternative drug that does not affect CYP3A4.

In addition, caution is required when capmatinib is used concomitantly with drugs with a risk of prolonging QT, anticoagulants, or immunosuppressants. For example, some antiarrhythmic drugs, some antifungals, or anticancer drugs may increase the risk of cardiotoxicity or bleeding. Before combined medication, it is necessary to conduct a detailed assessment of the patient's underlying disease, liver and kidney function, and potential drug interactions, and to regularly monitor blood pressure, electrocardiogram, and hematology indicators to ensure medication safety.

Reference materials:https://www.drugs.com/